

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO				Complete if Known <b>Application Number</b> 10/510,677 <b>Filing Date</b> 2003-04-09 <b>First Named Inventor</b> M. Parrington <b>Art Unit</b> 1642 <b>Examiner Name</b> Sean E. Aeder	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)					
				Attorney Docket No: <b>API-01-20-US</b>	
Sheet	1	of	1		

## US PATENT DOCUMENTS

Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A94	4,923,808	1990-05-08	Matteucci, et al.	Entire document
	A95	6,407,063	2002-06-18	Luiten, et al.	Entire document

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	B10	WO 98/29556A1	1998-07-09	The Wistar Institute	Entire document	
	B11	WO 99/46992A1	1999-09-23	Genzyme Corporation	Entire document	
	B12	WO 99/46988	1998-03-20	Genzyme Corporation	Entire document	

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	C28	BERINSTEIN, et al. Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review. J. Clin. Oncol. 20(8): 2197-2207 (2002)	
	C29	DUBENSKY, et al. Delivery Systems for Gene-Based Vaccines. Mol. Med. 6(9): 723-732 (2000)	
	C30	HODGE, et al. Diversified Prime and Boost Protocols Using Recombinant Vaccine Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses. Vaccine, vol. 15, issue 6/7, pp. 759-768 (1997)	
	C31	LEITNER, et al. Enhancement of Tumor-Specific Immune Response with Plasmid DNA Replicon Vectors. Cancer Res. 60: 51-55 (2000)	
	C32	MARSHALL, J. Carcinoembryonic Antigen-Based Vaccines. Semin. Oncol. (suppl. 8): 30-36 (2003)	
	C33	PARDOLL, D.M. Cancer vaccines. Nat. Med. 4: 525-531 (1998)	
	C34	PARMIANI, et al. Cancer Immunotherapy with Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? J. Natl. Cancer Inst. 94: 805-818 (2002)	
	C36	VAN DER BURG, et al. Induction of p53-Specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine. Clin. Cancer Res. 8: 1019-1027 (2002)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO 6460)

\* EXAMINER: (input all references considered, whether or not citation is in compliance with MPEP 809.02a; Drawings through citation if not in compliance and not corrected; Retain copy of this form with next communication to Applicant; Applicant's unique citation designation number (optional); Applicant is to place a check mark here if English language Translation is attached